Logo

American Heart Association

  142
  0


Final ID:

History and future of lipid therapeutics- a time of Renaissance

  • Rader, Daniel  ( UNIVERSITY OF PENNSYLVANIA , Philadelphia , Pennsylvania , United States )
  • Morris, Pamela  ( MEDICAL UNIVERSITY OF SC , Mt Pleasant , South Carolina , United States )
  • Author Disclosures:
    Daniel Rader: DO have relevant financial relationships ; Consultant:Alnylam:Active (exists now) ; Consultant:Verve:Active (exists now) ; Consultant:Novartis:Active (exists now) | Pamela Morris: DO have relevant financial relationships ; Researcher:Esperion:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
Discussant: CETP inhibition-is it time for a revival?

Watson Karol

Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Nicholls Stephen, Brunham Liam, Wuerdeman Erin, Neild Annie, Kling Douglas, Hsieh Andrew, Ference Brian, Laufs Ulrich, Banach Maciej, Mehran Roxana, Catapano Alberico, Nelson Adam, Davidson Michael, Ditmarsch Marc, Kastelein John, Ballantyne Christie, Ray Kausik, Navar Ann Marie, Nissen Steven, Goldberg Anne

More abstracts from these authors:
Discussant: VESALIUS-CV trial

Morris Pamela

Hypertension and AI based clinic guidance

Rader Daniel, Khera Amit, Kelly Melissa, Ebinger Joseph

You have to be authorized to contact abstract author. Please, Login
Not Available